CONSTELLATION TECHNOLOGIES LIMITED — AGM Information 2007

Nov 6, 2007

==> picture [97 x 77] intentionally omitted <==

COMPANY ANNOUNCEMENT CHANGE TO DATE OF ANNUAL GENERAL MEETING

The Company's Annual General Meeting of Agenix has been postponed and will now be held at 10.00am (Brisbane time) on Tuesday 11 December 2007 in the Surveyors Room, Conrad Treasury Hotel, Brisbane.

As announced to ASX on 1 November 2007, the Annual General Meeting was to be held on 27 November 2007.

However, the external mailing house misdirected the Notice of Meeting and the accompanying Annual Report so that shareholders have not received those documents.

The replacement Notice of Meeting and the Annual Report will be dispatched tomorrow, Thursday 8 November 2007.

The Australian Securities and Investments Commission has consented to the extension of time to hold the Annual General Meeting.

If you have any queries please contact Karl Schlobohm, Agenix Company Secretary, on 0419 721 007.

==> picture [155 x 48] intentionally omitted <==

Karl Schlobohm Company Secretary

7 November 2007

For more information about Agenix, please contact:

Mr Neil Leggett CEO and Managing Director Agenix Limited Ph: 61 7 3370 6310

Agenix Limited [ASX: AGX, OTC (NASDAQ): AGXLY ] is a biotechnology company based in Brisbane, Australia. Through its wholly owned subsidiaries, Agen Biomedical Ltd and Agenix Biopharmaceutical (Shanghai), the company has a strategic goal of building and developing a pipeline of therapeutic and imaging products.

120760v1c

Agen Biomedical’s lead candidate is its high-technology blood clot-imaging agent, ThromboView[] ,which has been undergoing human clinical trials in the United States, Canada and Australia. ThromboView[] uses radio-labelled antibodies to locate blood clots in the body, and could revolutionise the global clot diagnostic imaging market. Preparation is underway for commencement of a Phase II pulmonary embolism clinical trial in the United States and Canada. ThromboView[] is being developed with the assistance of the Australian Federal Government through its START scheme. ThromboView[] is a registered trademark of Agen Biomedical Ltd.

Agenix Biopharmaceutical (Shanghai) owns two associated Chinese life sciences companies. One, Shanghai Rui Guang Bio-Pharma Development Co., Ltd, is a biopharmaceutical company which has a pipeline of anti-viral drugs in development. Its lead product candidate, a hepatitis B virus drug, has successfully completed Phase III clinical trials in China and is awaiting China State Food and Drug Administration approval for market launch in China. The second, Shanghai Yi Sheng Yuan Pharmaceutical Co., Ltd, has a GMP certified manufacturing facility which has the capacity to produce 150 million tablets per annum (based on a 5-day working week at 8 hours per day).

www.agenix.com

120760v1c

2